Metronidazole control
PreclinicalSmall molecule
Metronidazole control is one of 18 small molecule programs targeting Bacterial Vaginosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Mycostatin
GGood Molecules, LLC
Approved
Decadron
AAspen Global Incorporated
Approved
Lactobacillus Acidophilus
UUniversiteit Antwerpen
Approved
Tindamax
MMission Pharmacal
Phase 3
Lactoferrin
UUniversità degli Studi di Ferrara
Phase 3
Conventional
PPopulation Health Research Institute
Phase 3
Lactoserum
SanofiApproved
Xifaxan
SSalix
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metronidazole control. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details